GSK, Sanofi stand by Zantac safety, try to calm investors

Aug. 12, 2022 5:39 AM ETPfizer Inc. (PFE), SNY, GSKHLNBy: Ravikash, SA News Editor9 Comments

Group business people and lawyers meeting together. Consulting in regard to the various contracts at meeting.

AmnajKhetsamtip/iStock via Getty Images

GSK (NYSE:GSK) and Sanofi (NASDAQ:SNY) defended their stance on heartburn drug Zantac (ranitidine) noting that since 2019 the researches conducted by different agencies and the companies have shown that there was no evidence

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.